In this Targeted Oncology video, Dr. Yoshiaki Nakamur discusses the utility of tissue-free ctDNA testing to predict recurrence in CRC patients.
In an article, Dr. Jasenka Piljac Zegarac summarizes Dr. Pashtoon M. Kasi and colleagues' findings related to ctDNA testing and well-being in CRC patients, which were presented at the 2024 ASCO Gastrointestinal Cancers Symposium. “ctDNA should be viewed as one added (and probably one of the most powerful) tool in the toolbox instead of a standalone variable.”—Dr. Pashtoon M. Kasi
European Society For Medical Oncology (ESMO) Congress 2024 Meeting is being held Friday, September 13th through Tuesday, September 17th, with numerous sessions and posters related to minimal residual disease in colorectal cancer. Highlighted Sessions and Posters Transcriptional features of stage IIT4N0/III colon cancer associated with residual disease and ctDNA status after surgery in the PEGASUS trial Preliminary analysis in Protector-C study: A prospective, multicenter cohort of utilizing circulating tumor DNA (ctDNA) methylation as postoperative surveillance for colorectal cancer Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in patients with resectable colorectal cancer: Updated analysis [...]
Drs. Shaalan Beg and Aparna Parikh present ASCO Daily News Podcast: How ctDNA Is Advancing Care for Patients With GI Cancers.
Cancer Network posts 12-episode series titled "ctDNA Analysis to Direct Treatment Decisions in Colorectal Cancer" in which expert panelists discuss clinical trials and circulating tumor DNA's (ctDNA) role in directing treatment.
Two episodes in Cancer Network series "Expert Insights Into Testing and Treatment for Metastatic Colorectal Cancer (mCRC) discuss the importance of circulating tumor DNA (ctDNA) in diagnosis, molecular testing, and treatment. EP. 2: The Evolving Landscape of Biomarker Testing in Metastatic Colorectal Cancer (mCRC) EP. 3: Common Testing Strategies for Molecular Markers in mCRC
Cancer Network posts 12-episode series titled "The Future of Decision-Making in Colorectal Cancer: ctDNA's Emerging Role" in which expert panelists discuss management of colorectal cancer using minimal residual disease (MRD) and circulating tumor DNA (ctDNA) testing and clinical trial outcomes.
Giulia Maddalena, a clinical oncologist by education and research trainee at MD Anderson Cancer Center, discusses how medical literature defines MRD and shares your survey results regarding what is your preferred definition. In cancer research, the importance of MRD has been growing, extending its relevance from hematologic malignancies to solid tumors. However, it stands for different definitions according to the specific context: Minimal Residual Disease, Molecular Residual Disease, or Measurable Residual Disease. This variability in terminology reflects the evolving nature of cancer diagnostics and treatment monitoring. Given the importance of clarity in medical terminology, we conducted a literature [...]
Health article discussing new blood test developed by Guardant Health that accurately identified colorectal cancer in 83% of patients with confirmed disease by detected circulating tumor DNA (ctDNA).
American Society of Clinical Oncology (ASCO) 2024 Annual Meeting is being held Friday, May 31st through Tuesday, June 4th, with numerous scheduled sessions related to minimal residual disease in colorectal cancer. Highlighted Sessions and Posters Use of MRD-Guided Strategies to Optimize Therapeutic Interventions Circulating Biomarkers: Who, What, Where, When, and Why? Gastrointestinal Cancer—Colorectal and Anal Abstracts and Posters Clinical validation of a novel circulating tumor DNA methylation assay for predicting recurrence of colorectal cancer in patients with curative-intent surgery by monitoring minimal residual disease. A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined [...]
© Copyright 2012 - 2026 | Avada Theme by ThemeFusion | All Rights Reserved | Powered by WordPress
